AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22650964 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral and intramuscular administration
Number of subjects: 320
Study 19541525 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling Fragmentation Irrigation (NFI)
Number of subjects: 96
Study 19541525 — intervention group
Group type: EXPERIMENTAL
Intervention: Bursoscopy (BS)
Number of subjects: 96
Study 19541525 — intervention group
Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 96
Study 17305711 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint (OS)
Number of subjects: 57
Study 17305711 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral treatment (CBT)
Number of subjects: 57
Study 15067411 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical rhinometry during positive nasal provocation tests with histamine and allergens
Number of subjects: 15
Study 15067411 — intervention group
Group type: COMPARATOR
Intervention: Optical rhinometry during negative provocation tests with allergens in non-allergics
Number of subjects: 15
Study 15067411 — intervention group
Group type: COMPARATOR
Intervention: Optical rhinometry during negative provocation tests with control solution
Number of subjects: 15
Study 15067411 — intervention group
Group type: COMPARATOR
Intervention: Optical rhinometry during decongestion with xylometazoline
Number of subjects: 15
Study 11233800 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin (320 mg orally for 7 days)
Number of subjects: 10
Study 11233800 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched, once daily for 7 days)
Number of subjects: 10
Study 9641172 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet intervention
Number of subjects: 840
Study 9641172 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood pressure intervention
Number of subjects: 840
Study 9641172 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger women
Number of subjects: 840
Study 9641172 — intervention group
Group type: EXPERIMENTAL
Intervention: Older women
Number of subjects: 840
Study 9641172 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall GFR decline
Number of subjects: 840
Study 9641172 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of study A
Number of subjects: 840
Study 9641172 — intervention group
Group type: EXPERIMENTAL
Intervention: Full cohort analysis
Number of subjects: 840
Study 7928327 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation therapy
Number of subjects: 23
Study 7928327 — intervention group
Group type: COMPARATOR
Intervention: Self-relaxation
Number of subjects: 23
Study 29694272 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthguard
Number of subjects: 24
Study 29694272 — intervention group
Group type: COMPARATOR
Intervention: No mouthguard
Number of subjects: 24
Study 28512184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP lowering (target SBP <120 mm Hg)
Number of subjects: 8164
Study 26281833 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of 1.0 Gy applied in 6 fractions of 1.0 Gy twice weekly (total dose 6.0 Gy)
Number of subjects: 127
Study 26281833 — intervention group
Group type: COMPARATOR
Intervention: Low single doses of 0.5 Gy applied in 12 fractions of 0.5 Gy three times weekly (total dose 6.0 Gy)
Number of subjects: 127
Study 23530977 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 80
Study 23530977 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 80
Study 23530977 — intervention group
Group type: COMPARATOR
Intervention: Strict control (target SBP <130 mm Hg)
Number of subjects: 80
Study 23530977 — intervention group
Group type: COMPARATOR
Intervention: Mild control (target SBP 130-139 mm Hg)
Number of subjects: 80
Study 21444210 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG)
Number of subjects: 2086
Study 19686527 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 117
Study 19686527 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 117
Study 19686527 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Advice
Number of subjects: 117
Study 19686527 — intervention group
Group type: EXPERIMENTAL
Intervention: MET + Cognitive-Behavioral Therapy (CBT)
Number of subjects: 117
Study 17942927 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanolimumab (human IgG1 antibody against CD4)
Number of subjects: 0
Study 17942927 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanolimumab
Number of subjects: 0
Study 15562884 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ibuprofen/pseudoephedrine/chlorpheniramine (200/30/2 mg)
Number of subjects: 0
Study 15562884 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ibuprofen/pseudoephedrine/chlorpheniramine (400/60/4 mg)
Number of subjects: 0
Study 15562884 — intervention group
Group type: COMPARATOR
Intervention: Combined pseudoephedrine/chlorpheniramine (30/2 mg)
Number of subjects: 0
Study 15562884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11146707 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined outreach initiative for pneumococcal and influenza vaccines
Number of subjects: 0
Study 11146707 — intervention group
Group type: COMPARATOR
Intervention: Pneumococcal vaccine
Number of subjects: 0
Study 11146707 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine
Number of subjects: 0
Study 11146707 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined outreach initiative targeted to people who had never received the pneumococcal vaccine or who had not received the influenza vaccine in the previous year
Number of subjects: 0
Study 11146707 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined outreach initiative as implemented
Number of subjects: 0
Study 11146707 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted initiative
Number of subjects: 0
Study 9623896 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: demineralized freeze-dried allograft, tetracycline, and porous hydroxyapatite
Number of subjects: 100
Study 9623896 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: demineralized freeze-dried allograft and tetracycline
Number of subjects: 100
Study 9623896 — intervention group
Group type: EXPERIMENTAL
Intervention: Defects with > or =10 mm probing depths in Group A
Number of subjects: 100
Study 9623896 — intervention group
Group type: EXPERIMENTAL
Intervention: Defects with > or =10 mm probing depths in Group B
Number of subjects: 100
Study 9623896 — intervention group
Group type: EXPERIMENTAL
Intervention: Defects with <10 mm probing depths in Group A
Number of subjects: 100
Study 9623896 — intervention group
Group type: EXPERIMENTAL
Intervention: Defects with <10 mm probing depths in Group B
Number of subjects: 100
Study 7870348 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Protein Diet (CPD) of 1 g protein/kg ideal body-weight/day
Number of subjects: 128
Study 7870348 — intervention group
Group type: COMPARATOR
Intervention: Low-Protein Diet (LPD) of 0.6 g protein/kg ideal body-weight/day
Number of subjects: 128
Study 3351998 — intervention group
Group type: EXPERIMENTAL
Intervention: Ender nails
Number of subjects: 100
Study 3351998 — intervention group
Group type: COMPARATOR
Intervention: McLaughlin technique (nail-plate fixation)
Number of subjects: 100
Study 29130570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI) at 10°C for 10 minutes
Number of subjects: 19
Study 29130570 — intervention group
Group type: COMPARATOR
Intervention: Partial-body cryotherapy (PBC) at -60°C for 30 seconds and -135°C for 2 minutes
Number of subjects: 19
Study 28166654 — intervention group
Group type: EXPERIMENTAL
Intervention: VM202 (64 mg) administered by intramuscular injections on days 0, 7, 14, and 21.
Number of subjects: 18
Study 28166654 — intervention group
Group type: EXPERIMENTAL
Intervention: VM202 (64 mg) administered by intramuscular injections.
Number of subjects: 18
Study 28166654 — intervention group
Group type: EXPERIMENTAL
Intervention: VM202 treatment.
Number of subjects: 18
Study 25672853 — intervention group
Group type: EXPERIMENTAL
Intervention: No-show patients
Number of subjects: 105
Study 25672853 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 105
Study 24004897 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based support for breastfeeding (6 months duration)
Number of subjects: 226
Study 21931228 — intervention group
Group type: EXPERIMENTAL
Intervention: Tartary buckwheat cookies (359.7 mg rutin equivalents/day)
Number of subjects: 62
Study 21931228 — intervention group
Group type: COMPARATOR
Intervention: Common buckwheat cookies (16.5 mg rutin equivalents/day)
Number of subjects: 62
Study 21931228 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of buckwheat cookies
Number of subjects: 62
Study 18245308 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel empirical disability weights for injury consequences
Number of subjects: 143
Study 18245308 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of novel empirical disability weights
Number of subjects: 143
Study 16879471 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg positioning (head-down group, n = 15)
Number of subjects: 30
Study 16879471 — intervention group
Group type: COMPARATOR
Intervention: Supine position (supine group, n = 15)
Number of subjects: 30
Study 12805245 — intervention group
Group type: EXPERIMENTAL
Intervention: Roasted salted almonds
Number of subjects: 38
Study 12805245 — intervention group
Group type: EXPERIMENTAL
Intervention: Roasted almond butter
Number of subjects: 38
Study 12805245 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw almonds
Number of subjects: 38
Study 12805245 — intervention group
Group type: COMPARATOR
Intervention: Control (no almonds)
Number of subjects: 38
Study 11054354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccination (5 microgram of recombinant hepatitis B vaccine, Engerix B) every 2 weeks up to a peak Ab titer of 1,000 IU/L or greater or 52 doses
Number of subjects: 97
Study 11054354 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vaccination (40 microgram at 0, 1, 2, and 6 months)
Number of subjects: 97
Study 11054354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccination
Number of subjects: 97
Study 11054354 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vaccination with peak Ab titer of 1,000 IU/L or greater
Number of subjects: 97
Study 8866093 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (high doses)
Number of subjects: 30
Study 8866093 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 1339712 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (oral, preoperatively)
Number of subjects: 18
Study 1339712 — intervention group
Group type: COMPARATOR
Intervention: Control group (no allopurinol)
Number of subjects: 18
Study 6391936 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 5 mg
Number of subjects: 84
Study 6391936 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg
Number of subjects: 84
Study 6391936 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 4 mg (IV)
Number of subjects: 84
Study 6391936 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 8 mg (IV)
Number of subjects: 84
Study 6391936 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg (IV)
Number of subjects: 84
Study 6391936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 31608548 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin glargine 100 U/mL (Gla-100)
Number of subjects: 2165
Study 29498534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal dexmedetomidine (0.2 μg/kg/h, titrated by 0.1 μg/kg/h every 15 min until a goal Richmond Agitation and Sedation Scale score of -1 or maximum rate of 0.7 μg/kg/h)
Number of subjects: 100
Study 29498534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 29498534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal dexmedetomidine
Number of subjects: 100
Study 27355400 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T) gel
Number of subjects: 470
Study 27355400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 470
Study 24468725 — intervention group
Group type: EXPERIMENTAL
Intervention: Canonical body posture (extended forearm and hand pointing distally)
Number of subjects: 0
Study 24468725 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-canonical body posture (forearm and hand pointing vertically up at 90°)
Number of subjects: 0
Study 24468725 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed body posture (elbow fully flexed at 180°)
Number of subjects: 0
Study 24468725 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversing the canonical posture of the finger
Number of subjects: 0
Study 24468725 — intervention group
Group type: EXPERIMENTAL
Intervention: Canonical orientation in egocentric space
Number of subjects: 0
Study 22668427 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg allicin adhesive tablets
Number of subjects: 96
Study 22668427 — intervention group
Group type: COMPARATOR
Intervention: Vehicle only (placebo)
Number of subjects: 96
Study 19910620 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection peribulbar anesthesia with a 16-mm needle
Number of subjects: 200
Study 19910620 — intervention group
Group type: COMPARATOR
Intervention: Double-injection peribulbar anesthesia with a 25-mm needle
Number of subjects: 200
Study 17409102 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric breast pump
Number of subjects: 65
Study 17409102 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-electric pedal breast pump
Number of subjects: 65
Study 17409102 — intervention group
Group type: COMPARATOR
Intervention: Hand (manual) expression
Number of subjects: 65
Study 15472677 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure-cut electrosurgical current
Number of subjects: 246
Study 15472677 — intervention group
Group type: COMPARATOR
Intervention: Blend electrosurgical current
Number of subjects: 246
Study 15472677 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 246
Study 11505257 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral inferior alveolar nerve block
Number of subjects: 38
Study 11505257 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral inferior alveolar nerve block
Number of subjects: 38
Study 9620807 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Number of subjects: 0
Study 9620807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8140047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg administered orally
Number of subjects: 6
Study 8140047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg administered to the colon via nasogastric intubation
Number of subjects: 6
Study 8140047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg administered rectally using a retention enema
Number of subjects: 6
Study 8140047 — intervention group
Group type: COMPARATOR
Intervention: Nonparenteral routes (oral, colonic, rectal)
Number of subjects: 6
Study 2846971 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive outpatient care with close monitoring, appointment reminders, and rescheduling of missed visits.
Number of subjects: 1001
Study 2846971 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 1001
Study 31844958 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 226
Study 31844958 — intervention group
Group type: EXPERIMENTAL
Intervention: ICA
Number of subjects: 226
Study 30621622 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin once per day (Group A)
Number of subjects: 2
Study 30621622 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin and 4.0 g of ecabet sodium (Group B)
Number of subjects: 2
Study 27714572 — intervention group
Group type: EXPERIMENTAL
Intervention: Transconjunctival single‐plane sclerocorneal incisions (TSSI)
Number of subjects: 64
Study 27714572 — intervention group
Group type: COMPARATOR
Intervention: Clear corneal incisions (CCI)
Number of subjects: 64
Study 26742006 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 40 mg daily for 2 or 5 years
Number of subjects: 0
Study 26742006 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment in patients with triple-negative and AR+ tumours
Number of subjects: 0
Study 26742006 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment in patients with AR- tumours
Number of subjects: 0
Study 26742006 — intervention group
Group type: COMPARATOR
Intervention: No endocrine treatment
Number of subjects: 0
Study 24668760 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 57
Study 24668760 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (control)
Number of subjects: 57
Study 22583535 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking reduction strategies during treatment
Number of subjects: 144
Study 22583535 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster sessions
Number of subjects: 144
Study 22583535 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline heavy drinking days
Number of subjects: 144
Study 22583535 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline abstinent/light drinking days
Number of subjects: 144
Study 22583535 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking reduction strategies
Number of subjects: 144
Study 19918752 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse high volume hemofiltration (pHVHF)
Number of subjects: 8
Study 19918752 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupled plasma filtration adsorption (CPFA)
Number of subjects: 8
Study 19918752 — intervention group
Group type: COMPARATOR
Intervention: Comparison of pHVHF and CPFA
Number of subjects: 8
Study 17242082 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic therapy (n = 81)
Number of subjects: 165
Study 17242082 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (n = 84)
Number of subjects: 165
Study 16075030 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure lowering using a fixed low-dose combination of perindopril and indapamide
Number of subjects: 11140
Study 16075030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive gliclazide-MR-based glucose control regimen
Number of subjects: 11140
Study 16075030 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effects of more intensive glucose control and tighter control of blood pressure
Number of subjects: 11140
Study 16075030 — intervention group
Group type: COMPARATOR
Intervention: Placebo for blood pressure lowering
Number of subjects: 11140
Study 16075030 — intervention group
Group type: COMPARATOR
Intervention: Standard guidelines-based glucose control regimen
Number of subjects: 11140
Study 12469525 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 0
Study 12469525 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening-tools for early identification and treatment of sleep-related breathing disorders
Number of subjects: 0
Study 12469525 — intervention group
Group type: EXPERIMENTAL
Intervention: Research into pathophysiological mechanisms and therapeutic possibilities of CVD related to OSA
Number of subjects: 0
Study 10440565 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity anticoagulation (AC), target range INR 1.1 < INR < 1.6
Number of subjects: 729
Study 10440565 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-intensity anticoagulation (AC), target range INR 2.5 < INR < 3.5
Number of subjects: 729
Study 10440565 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 150 mg/d
Number of subjects: 729
Study 8541368 — intervention group
Group type: EXPERIMENTAL
Intervention: Adelaide Activities Profile (AAP)
Number of subjects: 1799
Study 8541368 — intervention group
Group type: EXPERIMENTAL
Intervention: Adelaide Activities Profile (AAP) scales
Number of subjects: 1799
Study 2334630 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 9426 (250 micrograms kg‐1)
Number of subjects: 0
Study 2334630 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 9426 (500 micrograms kg‐1)
Number of subjects: 0
Study 2334630 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (control)
Number of subjects: 0
Study 479352 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) 1250 mg in divided doses
Number of subjects: 16
Study 479352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30293413 — intervention group
Group type: EXPERIMENTAL
Intervention: Vojant™
Number of subjects: 50
Study 30293413 — intervention group
Group type: COMPARATOR
Intervention: LigaSure™
Number of subjects: 50
Study 27927073 — intervention group
Group type: EXPERIMENTAL
Intervention: Team sport intervention
Number of subjects: 300
Study 27927073 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual sport intervention
Number of subjects: 300
Study 27927073 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 25282598 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone stabilization and taper
Number of subjects: 653
Study 24803436 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 3196
Study 24803436 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 3196
Study 22573231 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic-floor biofeedback training (PFBT) once a week for 3 months
Number of subjects: 52
Study 22573231 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving verbal instructions to contract the pelvic floor
Number of subjects: 52
Study 19052048 — intervention group
Group type: EXPERIMENTAL
Intervention: CT group (low-dose CT screening)
Number of subjects: 4104
Study 19052048 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4104
Study 17692111 — intervention group
Group type: EXPERIMENTAL
Intervention: Two phone interviews with parents regarding children's passive smoking status and consequences.
Number of subjects: 347
Study 17692111 — intervention group
Group type: COMPARATOR
Intervention: Sending a brief note concerning urinary cotinine test results to parents.
Number of subjects: 347
Study 15215800 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment
Number of subjects: 2457